These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 23774432)

  • 21. Phosphorothioate di- and trinucleotides as a novel class of anti-hepatitis B virus agents.
    Iyer RP; Jin Y; Roland A; Morrey JD; Mounir S; Korba B
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2199-205. PubMed ID: 15155222
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TP-RT domain interactions of duck hepatitis B virus reverse transcriptase in cis and in trans during protein-primed initiation of DNA synthesis in vitro.
    Boregowda RK; Adams C; Hu J
    J Virol; 2012 Jun; 86(12):6522-36. PubMed ID: 22514346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition.
    Mazzucco CE; Hamatake RK; Colonno RJ; Tenney DJ
    Antimicrob Agents Chemother; 2008 Feb; 52(2):598-605. PubMed ID: 18056280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Long-term clevudine therapy in nucleos(t)ide-naïve and lamivudine-experienced patients with hepatitis B virus-related chronic liver diseases].
    Lee HJ; Eun JR; Lee CH; Hwang JS; Suh JI; Kim BS; Jang BK
    Korean J Hepatol; 2009 Jun; 15(2):179-92. PubMed ID: 19581770
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Deviated binding of anti-HBV nucleoside analog E-CFCP-TP to the reverse transcriptase active site attenuates the effect of drug-resistant mutations.
    Yasutake Y; Hattori SI; Kumamoto H; Tamura N; Maeda K; Mitsuya H
    Sci Rep; 2024 Jul; 14(1):15742. PubMed ID: 38977798
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Development of clevudine resistance after switching from lamivudine in a patient with chronic hepatitis B].
    Koh KH; Kang CJ; Kim DH; Choi YW; Kim MJ; Cheong JY; Cho SW
    Korean J Gastroenterol; 2008 Nov; 52(5):325-8. PubMed ID: 19077481
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term treatment outcomes of clevudine in antiviral-naive patients with chronic hepatitis B.
    Kim SB; Song IH; Kim YM; Noh R; Kang HY; Lee HIe; Yang HY; Kim AN; Chae HB; Lee SH; Kim HS; Lee TH; Kang YW; Lee ES; Kim SH; Lee BS; Lee HY
    World J Gastroenterol; 2012 Dec; 18(47):6943-50. PubMed ID: 23322992
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses.
    Seignères B; Pichoud C; Martin P; Furman P; Trépo C; Zoulim F
    Hepatology; 2002 Sep; 36(3):710-22. PubMed ID: 12198665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tenofovir rescue regimen following prior suboptimal response to entecavir and adefovir combination therapy in chronic hepatitis B patients exposed to multiple treatment failures.
    Zhang Q; Han T; Nie CY; Ha FS; Liu L; Liu H
    J Med Virol; 2015 Jun; 87(6):1013-21. PubMed ID: 25716029
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative analysis of hepatitis B virus polymerase sequences required for viral RNA binding, RNA packaging, and protein priming.
    Jones SA; Clark DN; Cao F; Tavis JE; Hu J
    J Virol; 2014 Feb; 88(3):1564-72. PubMed ID: 24227865
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV-1 with HBV-associated Q151M substitution in RT becomes highly susceptible to entecavir: structural insights into HBV-RT inhibition by entecavir.
    Yasutake Y; Hattori SI; Hayashi H; Matsuda K; Tamura N; Kohgo S; Maeda K; Mitsuya H
    Sci Rep; 2018 Jan; 8(1):1624. PubMed ID: 29374261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure of the HIV-1 reverse transcriptase Q151M mutant: insights into the inhibitor resistance of HIV-1 reverse transcriptase and the structure of the nucleotide-binding pocket of Hepatitis B virus polymerase.
    Nakamura A; Tamura N; Yasutake Y
    Acta Crystallogr F Struct Biol Commun; 2015 Nov; 71(Pt 11):1384-90. PubMed ID: 26527265
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection model.
    Seignères B; Martin P; Werle B; Schorr O; Jamard C; Rimsky L; Trépo C; Zoulim F
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1842-52. PubMed ID: 12760857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of a novel long-acting 4'-modified nucleoside reverse transcriptase inhibitor against HBV.
    Higashi-Kuwata N; Hayashi S; Kumamoto H; Ogata-Aoki H; Das D; Venzon D; Hattori SI; Bulut H; Hashimoto M; Otagiri M; Takamune N; Kishimoto N; Davis DA; Misumi S; Kakuni M; Tanaka Y; Mitsuya H
    J Hepatol; 2021 May; 74(5):1075-1086. PubMed ID: 33333207
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine.
    Jacquard AC; Brunelle MN; Pichoud C; Durantel D; Carrouée-Durantel S; Trepo C; Zoulim F
    Antimicrob Agents Chemother; 2006 Mar; 50(3):955-61. PubMed ID: 16495257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of oxetanocin G, a novel nucleoside analog, on DNA synthesis by hepatitis B virus virions.
    Nagahata T; Kitagawa M; Matsubara K
    Antimicrob Agents Chemother; 1994 Apr; 38(4):707-12. PubMed ID: 7518217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transcomplementation of nucleotide priming and reverse transcription between independently expressed TP and RT domains of the hepatitis B virus reverse transcriptase.
    Lanford RE; Notvall L; Lee H; Beames B
    J Virol; 1997 Apr; 71(4):2996-3004. PubMed ID: 9060659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CMCdG, a Novel Nucleoside Analog with Favorable Safety Features, Exerts Potent Activity against Wild-Type and Entecavir-Resistant Hepatitis B Virus.
    Higashi-Kuwata N; Hayashi S; Das D; Kohgo S; Murakami S; Hattori SI; Imoto S; Venzon DJ; Singh K; Sarafianos SG; Tanaka Y; Mitsuya H
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison between clevudine and entecavir treatment for antiviral-naïve patients with chronic hepatitis B.
    Kim HJ; Park DI; Park JH; Cho YK; Sohn CI; Jeon WK; Kim BI
    Liver Int; 2010 Jul; 30(6):834-40. PubMed ID: 20408946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clevudine for the treatment of chronic hepatitis B virus infection.
    Hui CK; Lau GK
    Expert Opin Investig Drugs; 2005 Oct; 14(10):1277-84. PubMed ID: 16185170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.